155 related articles for article (PubMed ID: 28745577)
1. Advanced cancer pain: the search for genetic factors correlated with interindividual variability in opioid requirement.
Matic M; Jongen JL; Elens L; de Wildt SN; Tibboel D; Sillevis Smitt PA; van Schaik RH
Pharmacogenomics; 2017 Aug; 18(12):1133-1142. PubMed ID: 28745577
[TBL] [Abstract][Full Text] [Related]
2. Single-Nucleotide Polymorphisms in TAOK3 Are Associated With High Opioid Requirement for Pain Management in Patients With Advanced Cancer Admitted to a Tertiary Palliative Care Unit.
Gutteridge T; Kumaran M; Ghosh S; Fainsinger R; Klepstad P; Tarumi Y; Damaraju S; Baracos VE
J Pain Symptom Manage; 2018 Oct; 56(4):560-566. PubMed ID: 30031856
[TBL] [Abstract][Full Text] [Related]
3. Exploring joint effects of genes and the clinical efficacy of morphine for cancer pain: OPRM1 and COMT gene.
Reyes-Gibby CC; Shete S; Rakvåg T; Bhat SV; Skorpen F; Bruera E; Kaasa S; Klepstad P
Pain; 2007 Jul; 130(1-2):25-30. PubMed ID: 17156920
[TBL] [Abstract][Full Text] [Related]
4. Association of the OPRM1 and COMT genes' polymorphisms with the efficacy of morphine in Tunisian cancer patients: Impact of the high genetic heterogeneity in Tunisia?
Chatti I; Creveaux I; Woillard JB; Langlais S; Amara A; Ben Fatma L; Saad A; Gribaa M; Libert F
Therapie; 2016 Oct; 71(5):507-513. PubMed ID: 27288213
[TBL] [Abstract][Full Text] [Related]
5. OPRM1 c.118A>G Polymorphism and Duration of Morphine Treatment Associated with Morphine Doses and Quality-of-Life in Palliative Cancer Pain Settings.
Hajj A; Halepian L; Osta NE; Chahine G; Kattan J; Rabbaa Khabbaz L
Int J Mol Sci; 2017 Mar; 18(4):. PubMed ID: 28346387
[TBL] [Abstract][Full Text] [Related]
6. Genetic Contribution in Low Back Pain: A Prospective Genetic Association Study.
Margarit C; Roca R; Inda MD; Muriel J; Ballester P; Moreu R; Conte AL; Nuñez A; Morales D; Peiró AM
Pain Pract; 2019 Nov; 19(8):836-847. PubMed ID: 31269327
[TBL] [Abstract][Full Text] [Related]
7. Effects of the OPRM1 A118G Polymorphism (rs1799971) on Opioid Analgesia in Cancer Pain: A Systematic Review and Meta-Analysis.
Yu Z; Wen L; Shen X; Zhang H
Clin J Pain; 2019 Jan; 35(1):77-86. PubMed ID: 30028366
[TBL] [Abstract][Full Text] [Related]
8. Human Genetic Variability Contributes to Postoperative Morphine Consumption.
De Gregori M; Diatchenko L; Ingelmo PM; Napolioni V; Klepstad P; Belfer I; Molinaro V; Garbin G; Ranzani GN; Alberio G; Normanno M; Lovisari F; Somaini M; Govoni S; Mura E; Bugada D; Niebel T; Zorzetto M; De Gregori S; Molinaro M; Fanelli G; Allegri M
J Pain; 2016 May; 17(5):628-36. PubMed ID: 26902643
[TBL] [Abstract][Full Text] [Related]
9. Pain polymorphisms and opioids: An evidence based review.
Vieira CMP; Fragoso RM; Pereira D; Medeiros R
Mol Med Rep; 2019 Mar; 19(3):1423-1434. PubMed ID: 30592275
[TBL] [Abstract][Full Text] [Related]
10. Genetic Factors Associated With Pain Severity, Daily Opioid Dose Requirement, and Pain Response Among Advanced Cancer Patients Receiving Supportive Care.
Yennurajalingam S; Astolfi A; Indio V; Beccaro M; Schipani A; Yu R; Shete S; Reyes-Gibby C; Lu Z; Williams JL; Yeun SC; Anderson AE; Biasco G; Bruera E
J Pain Symptom Manage; 2021 Oct; 62(4):785-795. PubMed ID: 33848569
[TBL] [Abstract][Full Text] [Related]
11. Genetic Influences of OPRM1, OPRD1 and COMT on Morphine Analgesia in a Multi-Modal, Multi-Tissue Human Experimental Pain Model.
Nielsen LM; Christrup LL; Sato H; Drewes AM; Olesen AE
Basic Clin Pharmacol Toxicol; 2017 Jul; 121(1):6-12. PubMed ID: 28084056
[TBL] [Abstract][Full Text] [Related]
12. The role of hydromorphone and OPRM1 in postoperative pain relief with hydrocodone.
Boswell MV; Stauble ME; Loyd GE; Langman L; Ramey-Hartung B; Baumgartner RN; Tucker WW; Jortani SA
Pain Physician; 2013; 16(3):E227-35. PubMed ID: 23703421
[TBL] [Abstract][Full Text] [Related]
13. Candidate gene analyses for acute pain and morphine analgesia after pediatric day surgery: African American versus European Caucasian ancestry and dose prediction limits.
Li J; Wei Z; Zhang J; Hakonarson H; Cook-Sather SD
Pharmacogenomics J; 2019 Dec; 19(6):570-581. PubMed ID: 30760877
[TBL] [Abstract][Full Text] [Related]
14. Selection of opioids for cancer-related pain using a biomarker: a randomized, multi-institutional, open-label trial (RELIEF study).
Matsuoka H; Tsurutani J; Chiba Y; Fujita Y; Terashima M; Yoshida T; Sakai K; Otake Y; Koyama A; Nishio K; Nakagawa K
BMC Cancer; 2017 Oct; 17(1):674. PubMed ID: 28985716
[TBL] [Abstract][Full Text] [Related]
15. Gene polymorphisms of OPRM1 A118G and ABCB1 C3435T may influence opioid requirements in Chinese patients with cancer pain.
Gong XD; Wang JY; Liu F; Yuan HH; Zhang WY; Guo YH; Jiang B
Asian Pac J Cancer Prev; 2013; 14(5):2937-43. PubMed ID: 23803057
[TBL] [Abstract][Full Text] [Related]
16. Opioid treatment failure in cancer patients: the role of clinical and genetic factors.
Oosten AW; Matic M; van Schaik RH; Look MP; Jongen JL; Mathijssen RH; van der Rijt CC
Pharmacogenomics; 2016 Aug; 17(13):1391-403. PubMed ID: 27472837
[TBL] [Abstract][Full Text] [Related]
17. Evidence Regarding Pharmacogenetics in Pain Management and Cancer.
Smith DM; Figg WD
Oncologist; 2023 Mar; 28(3):189-192. PubMed ID: 36718020
[TBL] [Abstract][Full Text] [Related]
18. OPRM1 Methylation Contributes to Opioid Tolerance in Cancer Patients.
Viet CT; Dang D; Aouizerat BE; Miaskowski C; Ye Y; Viet DT; Ono K; Schmidt BL
J Pain; 2017 Sep; 18(9):1046-1059. PubMed ID: 28456745
[TBL] [Abstract][Full Text] [Related]
19. Opioid response in paediatric cancer patients and the Val158Met polymorphism of the human catechol-O-methyltransferase (COMT) gene: an Italian study on 87 cancer children and a systematic review.
Lucenteforte E; Vannacci A; Crescioli G; Lombardi N; Vagnoli L; Giunti L; Cetica V; Coniglio ML; Pugi A; Bonaiuti R; Aricò M; Giglio S; Messeri A; Barale R; Giovannelli L; Mugelli A; Maggini V
BMC Cancer; 2019 Jan; 19(1):113. PubMed ID: 30704436
[TBL] [Abstract][Full Text] [Related]
20. Morphine Versus Oxycodone for Cancer Pain Using a Catechol-O-methyltransferase Genotype Biomarker: A Multicenter, Randomized, Open-Label, Phase III Clinical Trial (RELIEF Study).
Matsuoka H; Tsurutani J; Chiba Y; Fujita Y; Sakai K; Yoshida T; Nakura M; Sakamoto R; Makimura C; Ohtake Y; Tanaka K; Hayashi H; Takeda M; Okuno T; Takegawa N; Haratani K; Koyama A; Nishio K; Nakagawa K
Oncologist; 2023 Mar; 28(3):278-e166. PubMed ID: 36426809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
